




A. ACR20




B. ACR50




C. ACR70



D. SDAI



E. CDAI

**Supplementary Fig. S1.**

The proportion of patients achieving ACR20 (A), ACR50 (B) and ACR70 (C) responses and the change from baseline in SDAI score (D) and CDAI score (E) over time up to week 52.

* $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$ vs. placebo by logistic regression for CDAI and SDAI; by ANOVA for HAQ-DI and DAS28-hsCRP.

ANOVA: analysis of variance; ACR: American College of Rheumatology; CDAI: Clinical Disease Activity Index; LSM: least squares mean; mLOCF: modified last observation carried forward; NRI: non-responder imputation; SDAI: Simplified Disease Activity Index.